Unfortunately, some patients with NSCLC carrying EGFR mutations do not respond to EGFR inhibitors, suggesting EGFR mutation-independent mechanisms such as co-occurrence of KRAS mutations (18). Here, EGFR is linked to non-small cell lung carcinoma.